Castelli D, Colin L, Camel E, Ries G
RoC Laboratoires de Dermo-esthétique, Colombes, France.
Contact Dermatitis. 1998 Mar;38(3):123-6. doi: 10.1111/j.1600-0536.1998.tb05676.x.
The clinical efficiency of mitigating contact dermatitis with a Ginkgo biloba extract and carboxymethyl-beta-1,3-glucan formulation was investigated in a double-blind versus placebo study using 22 subjects (Caucasian women aged 22-55 years) with allergic contact dermatitis from various substances in the European standard series. The formulation was applied to intact skin 2X a day for 2 weeks ("in use" application) prior to a single application of a selected contact allergen under a Finn Chamber for 24 h. Readings were carried out in a blind study by a dermatologist 2 and 3 days after patch removal. Representative photographs were taken of treated, placebo and untreated test areas. 68.2% of the panelists showed significantly reduced skin reactivity (p = 0.037*) on the treated site 2 days after patch removal, versus untreated and/or placebo sites. This finding indicates that the Ginkgo biloba/carboxymethyl-beta-1,3-glucan formulation can mitigate against allergic contact dermatitis.
在一项双盲对照安慰剂研究中，对22名（年龄在22 - 55岁的白种女性）患有因欧洲标准系列中各种物质引起的过敏性接触性皮炎的受试者，研究了银杏叶提取物和羧甲基-β-1,3-葡聚糖制剂减轻接触性皮炎的临床效果。在使用芬兰小室单次涂抹选定的接触性变应原24小时之前，该制剂每天两次涂抹于完整皮肤上，持续2周（“使用中”涂抹）。在去除贴片后2天和3天，由皮肤科医生在盲法研究中进行读数。对治疗、安慰剂和未治疗的测试区域拍摄代表性照片。与未治疗和/或安慰剂部位相比，68.2%的小组成员在去除贴片后2天，治疗部位的皮肤反应性显著降低（p = 0.037*）。这一发现表明银杏叶/羧甲基-β-1,3-葡聚糖制剂可以减轻过敏性接触性皮炎。
